The success of suzetrigine supports the goal of moving beyond relieving pain to doing so safely, without perpetuating cycles ...

Acute Pain Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The report provides a detailed analysis of the current acute pain marketed drugs and ...

After years of investment to upgrade its manufacturing capabilities, Pacira BioSciences figures it’s time to retire a facility that has been running for more than a decade. | After years spent ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first ...

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

Lower levels of certain vitamins and minerals were found to be associated with chronic pain in a study led by researchers at ...

Journavx, which is used to treat pain, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

An estimated one in four Americans suffers from chronic pain. For one in 10 of those sufferers, their pain is so intense, it ...

Treatment with HCCP led to significant improvements in pain, sleep quality, mood, and overall quality of life in patients with PNI.